Latest News and Press Releases

Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...

MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...

Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in AustraliaNew clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to...

Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales)USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales)Global FY23 sales of A$1.80 M (136% increase on FY22 sales) ...

MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the...

Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...

Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...

Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily...

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...